A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab

Table 2 Bone markers and densitometry data at baseline and 1 year later

Group	Baseline	1 year	P
Control
Osteocalcin	21.2 ± 13.4	20.7 ± 11.5	NS
CTX-I	418 ± 227	391 ± 259	NS
Parathyroid hormone	32.0 ± 19.1	36.0 ± 19.7	NS
25-hydroxycholecalciferol	21.2 ± 10.4	22.8 ± 10.5	NS
Femoral neck BMD	0.797 ± 0.162	0.770 ± 0.162	<0.001
Lumbar BMD	0.896 ± 0.142	0.861 ± 0.142	<0.001
Infliximab
Osteocalcin	18.4 ± 9.7	15.7 ± 10.9	NS
CTX-I	482 ± 386	452 ± 271	NS
Parathyroid hormone	29.1 ± 15.4	32.6 ± 15.5	NS
25-hydroxycholecalciferol	17.9 ± 10.1	19.6 ± 9.2	NS
Femoral neck BMD	0.807 ± 0.156	0.809 ± 0.151	NS
Lumbar BMD	0.930 ± 0.142	0.928 ± 0.136	NS

Values are shown for each parameter at baseline and at 1 year, expressed as mean ± standard deviation. In each group, data were compared using the Student's paired t-test for continuous variables, between baseline and 1 year. BMD, bone mineral density; CTX-I, C-terminal cross-linking telopeptide of type I collagen.

ISSN: 1478-6362